Alexandra Tolia
Direttore/Membro del Consiglio presso FORMAC Pharmaceuticals NV
Provenienza dei contatti di primo grado di Alexandra Tolia
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.
31
| Subsidiary | Investment Managers | 31 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.
15
| Holding Company | Biotechnology | 15 |
FORMAC Pharmaceuticals NV
FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium.
9
| Holding Company | Pharmaceuticals: Generic | 9 |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.
9
| Holding Company | Pharmaceuticals: Major | 9 |
FEops NV
FEops NV Medical SpecialtiesHealth Technology FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.
8
| Holding Company | Medical Specialties | 8 |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.
6
| Private Company | Investment Managers | 6 |
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Hunza Management SARL
Hunza Management SARL Investment ManagersFinance Hunza Management SARL is a private equity firm headquartered in Luxembourg. The current firm was established in 1998 to manage Hunza Ventures, the venture capital investment vehicle of the family of the retired Belgian entrepreneur Guy Ullens. Baron Guy Ullens de Schooten and the Wittouck family built up and controlled the diversified European food manufacturing group Artal, based in Luxembourg and historically focused on the Belgian sugar industry.
2
| Private Company | Investment Managers | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Alexandra Tolia tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | President Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
KBC Asset Management NV
KBC Asset Management NV Investment ManagersFinance KBC Asset Management NV (KBC AM) is the wholly-owned asset management subsidiary of KBC Bank NV, itself a subsidiary of KBC Group SA/NV (XB: KBC; ADR: KBCSY) in Belgium. The firm was founded in 2000 and is previously a division of KBC Bank. Headquartered in Brussels, KBC AM provides asset management services to private individuals, corporate clients and institutions. They also manage a range of mutual funds across various asset classes, markets and strategies. | Investment Managers | Chairman Analyst-Equity | |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Private Equity Investor Private Equity Investor | |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director of Finance/CFO Director/Board Member | |
Gimv (Private Equity)
Gimv (Private Equity) Investment ManagersFinance Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium. | Investment Managers | Director/Board Member Private Equity Investor Private Equity Investor | |
University of Utrecht | College/University | Graduate Degree Graduate Degree | |
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Ghent University | College/University | Doctorate Degree Graduate Degree Director/Board Member | |
Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
Université Libre de Bruxelles | College/University | Graduate Degree Graduate Degree | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
Vlerick Leuven Gent Management School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Université Catholique de Louvain | College/University | Doctorate Degree Corporate Officer/Principal Investor Relations Contact Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree | |
MERUS N.V. | Biotechnology | Director/Board Member Chief Operating Officer | |
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
CELYAD ONCOLOGY SA | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member Director/Board Member | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
VIA-Invest Vlaanderen NV
VIA-Invest Vlaanderen NV Financial ConglomeratesFinance VIA-Invest Vlaanderen NV provides investment services. It invests in various project companies (SPVs) with capital and subordinated loans. The firm also provides legal and financial, communications and facilities related advice. The company is headquartered in Brussels, Belgium. | Financial Conglomerates | Chief Investment Officer Chief Investment Officer | |
Amakem NV
Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Chairman Director/Board Member Director/Board Member Director/Board Member | |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder Chief Tech/Sci/R&D Officer | |
University of Antwerp | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
STAT-Dx Life SL
STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
DEME Blue Energy NV
DEME Blue Energy NV Engineering & ConstructionIndustrial Services DEME Blue Energy NV operates as a holding company with interests in dredging and hydraulic engineering. The company was founded on February 15, 2010 and is headquartered in Zwijndrecht, Belgium. | Engineering & Construction | Director/Board Member Director/Board Member | |
Q-Biologicals NV
Q-Biologicals NV BiotechnologyHealth Technology Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Chairman | |
Via R4-Gent NV
Via R4-Gent NV MiscellaneousMiscellaneous Via R4-Gent NV operates as a holding company with interest in designing, financing, constructing and maintaining of roads. It is a Public Private Partnership project upgrading the road infrastructure around the city of Ghent. The company is headquartered in Brussels, Belgium. | Miscellaneous | Director/Board Member Director/Board Member | |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
Storm Holding NV
Storm Holding NV Electric UtilitiesUtilities Storm Holding NV owns and operates a portfolio of wind farms. It distributes electricity to private and government sectors. The company was founded in December 2011 and is Antwerp, Belgium. | Electric Utilities | Director/Board Member Director/Board Member | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
Bioxodes SA
Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Storm Holding 2 NV
Storm Holding 2 NV Engineering & ConstructionIndustrial Services Storm Holding 2 NV constructs and operates wind farms. The company is based in Antwerp, Belgium and has subsidiaries in Belgium. | Engineering & Construction | Director/Board Member Director/Board Member | |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Chairman Director/Board Member Director/Board Member | |
IMMUNIC, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Storm Holding 3 NV
Storm Holding 3 NV Financial ConglomeratesFinance Storm Holding 3 NV engages in the operation of wind farms. It invests in companies that carry out business activities related to renewable energy. The company was founded on December 21, 2018 and is headquartered in Antwerp, Belgium. | Financial Conglomerates | Director/Board Member Director/Board Member | |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
Belgio | 33 |
Stati Uniti | 7 |
Paesi Bassi | 7 |
Spagna | 3 |
Germania | 3 |
Settori
Health Technology | 26 |
Finance | 9 |
Consumer Services | 8 |
Commercial Services | 6 |
Industrial Services | 3 |
Posizioni
Director/Board Member | 409 |
Private Equity Investor | 77 |
Corporate Officer/Principal | 65 |
Independent Dir/Board Member | 48 |
Chairman | 47 |
Contatti più connessi
Insiders | |
---|---|
Chris Buyse | 39 |
Marijn Dekkers | 35 |
Dieter Weinand | 32 |
Alain Parthoens | 29 |
Vincent Ossipow | 22 |
John Paul de Koning | 21 |
Edward van Wezel | 20 |
Luc Gijsens | 20 |
José Antonio Mesa Cejudo | 20 |
Pamela Klein | 19 |
Joël Jean-Mairet | 17 |
Lena Elisabeth Svanberg | 16 |
Karl Nägler | 16 |
Chris de Jonghe | 15 |
Vincent Brichard | 15 |
- Borsa valori
- Insiders
- Alexandra Tolia
- Connessioni Società